2. Academic Validation
  3. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  • J Med Chem. 1997 Jul 18;40(15):2296-303. doi: 10.1021/jm970367n.
J M Hamby 1,  C J Connolly,  M C Schroeder,  R T Winters,  H D Showalter,  R L Panek,  T C Major,  B Olsewski,  M J Ryan,  T Dahring,  G H Lu,  J Keiser,  A Amar,  C Shen,  A J Kraker,  V Slintak,  J M Nelson,  D W Fry,  L Bradford,  H Hallak,  A M Doherty
Affiliations

Affiliation

  • 1 Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105, USA. HambyJ@aa.wl.com
PMID: 9240345 DOI: 10.1021/jm970367n
Abstract

Screening of a compound library for inhibitors of the Fibroblast Growth Factor (FGFR) and platelet-derived growth factor (PDGFR) Receptor Tyrosine Kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The initial lead, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butylurea (4b, PD-089828), was found to be a broadly active tyrosine kinase inhibitor. Compound 4b inhibited the PDGFR, FGFR, EGFR, and c-src tyrosine kinases with IC50 values of 1.11, 0.13, 0.45, and 0.22 microM, respectively. Subsequent SAR studies led to the synthesis of new analogs with improved potency, solubility, and bioavailability relative to the initial lead. For example, the introduction of a [4-(diethylamino)butyl]amino side chain into the 2-position of 4b afforded compound 6c with enhanced potency and bioavailability. Compound 6c inhibited PDGF-stimulated vascular smooth muscle cell proliferation with an IC50 of 0.3 microM. Furthermore, replacement of the 6-(2,6-dichlorophenyl) moiety of 4b with a 6-(3',5'-dimethoxyphenyl) functionality produced a highly selective FGFR tyrosine kinase inhibitor 4e. Compound 4e inhibited the FGFR tyrosine kinase with an IC50 of 0.060 microM, whereas IC50s for the inhibition of the PDGFR, FGFR, EGFR, c-src, and InsR tyrosine kinases for this compound (4e) were all greater than 50 microM.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z